Bial drops Parkinson’s therapy after it fails to slow disease in trial
BIA 28-6156, a small-molecule therapy developed by Bial for GBA-related Parkinson’s disease, did not slow disease progression in a Phase 2 clinical trial involving people with mutations in the GBA1…